In a study on drug resistance in pancreatic cancer, the use of cell membrane camouflaged and bufalin-loaded nanoparticles for the treatment of pancreatic cancer revealed that bufalin reverses the drug resistance of pancreatic cancer cells by regulating the nucleotide binding oligomerization domain containing 2/nuclear Factor Kappa B/ATP-binding cassette transporter (NOD2/NF-κB/ABC) signaling pathway [202]. The gene discussed is NFKB1; the disease is pancreatic neoplasm.